Pradžia › Mielofibrozė › Texas › Houston
Mielofibrozė klinikiniai tyrimai Houston, TX
19 tyrimai dėl Mielofibrozė ieško dalyvių vietose Houston ir aplinkui (apytiksliai 30 mylių spinduliu). Atidarykite tyrimą, kad pamatytumėte, kas gali dalyvauti ir kaip susisiekti su tyrimo komanda.
Oficialus tyrimo tekstas (anglų kalba)
Ieškote dalyvių tyrimui? Pateikite jį šio puslapio viršuje – $99 už 30 dienų →
A Study of Oral Nuvisertib (TP-3654) in Patients With Myelofibrosis
Renkami dalyviai1/2 fazė
- MD Anderson Cancer Center, Houston
A Phase 3 Study of Pelabresib (DAK539) and Ruxolitinib in Myelofibrosis (MF)
Renkami dalyviai3 fazė
- MD Anderson Cancer Center, Houston
A Phase 1 Study of PRT12396 in Participants With Select Myeloproliferative Neoplasms
Renkami dalyviai1 fazė
- The University of Texas, MD Anderson Cancer Center, Houston
A Study to Compare Elritercept to Placebo in Adults With Myelofibrosis and Anemia Who Are Taking Ruxolitinib
Renkami dalyviai3 fazė
- MD Anderson Cancer Center, Houston
- The University of Utah-Huntsman Cancer Institute, Houston
- LUMI Research, Houston
Study of DISC-0974 (RALLY-MF) in Participants With Myelofibrosis or Myelodysplastic Syndrome and Anemia
Renkami dalyviai1/2 fazė
- MD Anderson, Houston
A Phase 1 Study of LY5830966 in Participants With Primary Myelofibrosis (PMF), Post-Polycythemia Vera Myelofibrosis (PPV-MF), or Post-Essential Thrombocythemia Myelofibrosis (PET-MF) Who Have Been Failed by a Type I JAK2 Inhibitor (JAK2i)
Renkami dalyviai1 fazė
- MD Anderson Cancer Center, Houston
High Dose Ruxolitinib and Allogeneic Stem Cell Transplantation in Myelofibrosis Patients With Splenomegaly
Renkami dalyviai2 fazė
- MD Anderson Cancer Center, Houston
Study of INCA036978 in Participants With Myeloproliferative Neoplasms
Renkami dalyviai1 fazė
- University of Texas M. D. Anderson Cancer Center, Houston
Phase I/II Clinical Trial of Axatilimab, a CSF1R Monoclonal Antibody, in Combination With Ruxolitinib as Therapy for Patients With Myelofibrosis (MF) and Chronic Myelomonocytic Leukemia (CMML)
Renkami dalyviai1/2 fazė
- The University of Texas M. D. Anderson Cancer Center, Houston
Open Label Phase 1/2 Study of Tasquinimod in Patients With Primary Myelofibrosis (PMF), Post-Polycythemia Vera Myelofibrosis (Post-PV MF), or Post-Essential Thrombocytosis Myelofibrosis (Post-ET MF)
Renkami dalyviai1/2 fazė
- MD Anderson Cancer Center, Houston
Study of Oral Administration of LP-118 in Patients With Relapsed or Refractory CLL, SLL, MDS, MDS/MPN, AML, CMML-2, MPN-BP, ALL, MF, NHL, RT, MM or T-PLL.
Renkami dalyviai1 fazė
- MD Anderson Cancer Center, Houston
Study of Momelotinib in Combination With Luspatercept in Participants With Transfusion Dependent Myelofibrosis
Renkami dalyviai2 fazė
- GSK Investigational Site, Houston
A Study to Evaluate INCA033989 Administered as a Monotherapy or in Combination With Ruxolitinib in Participants With Myeloproliferative Neoplasms
Renkami dalyviai1 fazė
- Md Anderson Cancer Center, Houston
A Platform Protocol to Investigate Post-Transplant Cyclophosphamide-Based Graft-Versus-Host Disease Prophylaxis in Patients With Hematologic Malignancies Undergoing Mismatched Unrelated Donor Peripheral Blood Stem Cell Transplantation
Renkami dalyviai2 fazė
- MD Anderson, Houston
A Study of Selinexor Monotherapy in Subjects With JAK Inhibitor-naïve Myelofibrosis and Moderate Thrombocytopenia
Renkami dalyviai2 fazė
- MD Anderson, Houston
SYNERGY-AI: Artificial Intelligence Based Precision Oncology Clinical Trial Matching and Registry
Renkami dalyviaiStebimasis tyrimas
- Massive Bio SYNERGY-AI site, Houston
Study of Navtemadlin add-on to Ruxolitinib in JAK Inhibitor-Naïve Patients With Myelofibrosis Who Have a Suboptimal Response to Ruxolitinib
Renkami dalyviai3 fazė
- U.T. MD Anderson Cancer Center, Houston
Leading in MPNs Beyond Ruxolitinib in Combo With T-Regs
Renkami dalyviai1 fazė
- The University of Texas MD Anderson Cancer Center, Houston
Study of TL-895 Combined With Ruxolitinib in JAKi Treatment-Naïve MF Subjects and Subjects With MF Who Have a Suboptimal Response to Ruxolitinib
Renkami dalyviai1/2 fazė
- The University of Texas MD Anderson Cancer Center, Houston
Mielofibrozė tyrimai kituose miestuose
- New York City, NY18 tyrimai
- Boston, MA12 tyrimai
- Durham, NC12 tyrimai
- Columbus, OH11 tyrimai
- Seattle, WA11 tyrimai
- Salt Lake City, UT10 tyrimai
- Miami, FL10 tyrimai
- Nashville, TN9 tyrimai
- Cleveland, OH9 tyrimai
- Tampa, FL9 tyrimai
- Atlanta, GA9 tyrimai
- Baldwin Park, CA9 tyrimai
Kiti tyrimai Houston
- Nedidelinių ląstelių plaučių vėžys145 tyrimai
- Krūties vėžys126 tyrimai
- Vėžys (visų tipų)121 tyrimas
- Metastatinis vėžys104 tyrimai
- Storosios ir tiesiosios žarnos vėžys102 tyrimai
- Kiaušidžių vėžys89 tyrimai
- Ūmi mieloidinė leukemija85 tyrimai
- Plaučių vėžys78 tyrimai
- Prostatos vėžys76 tyrimai
- Endometrio vėžys68 tyrimai
- Kasos vėžys61 tyrimas
- Melanoma59 tyrimai
Iš ClinicalTrials.gov, duomenys gauti 2026-10-05. Kiekvienas tyrimas nustato savo tinkamumo kriterijus; tyrimo komanda sprendžia, kas gali dalyvauti.